Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 7/20 | 0.60 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.60 |
| ▸ | LTA4H | P09960 | 6/20 | 0.60 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785769 | 0.87 | GAA (0.60) | LTA4HKDM4EHRH3 | |
| SCHEMBL5778640 | 0.85 | SIGMAR1 (0.64) | KDM4EHRH3 | |
| SCHEMBL7353075 | 0.84 | PSMB1 (0.66) | PSMB1PSMB5LTA4HPSMB2KDM4E | |
| SCHEMBL11876046 | 0.83 | LTA4H (0.71) | PSMB1PSMB5LTA4HPSMB2KDM4E | |
| SCHEMBL23742244 | 0.83 | PSMB1 (0.69) | PSMB1PSMB5LTA4HPSMB2KDM4E | |
| SCHEMBL11881017 | 0.82 | LTA4H (0.69) | PSMB1PSMB5LTA4HPSMB2KDM4E | |
| SCHEMBL14970684 | 0.80 | LTA4H (0.82) | PSMB1PSMB5LTA4HPSMB2KDM4E | |
| SCHEMBL15257179 | 0.80 | LTA4H (0.82) | PSMB1PSMB5LTA4HPSMB2KDM4E | |
| SCHEMBL15492001 | 0.79 | HRH3 (0.66) | PSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL11880228 | 0.79 | KDM4E (0.70) | PSMB1PSMB5LTA4HPSMB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987042-B1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2015-01-21 | — | — | EP | disclosed |
| US-8853208-B2 | Amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20090076002-A1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076002-A1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | AADAT, PNMT, MCHR1 | PSMB1 4627/4885PSMB5 3687/4885LTA4H 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.